ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 309 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
309 citing papers in PubMed, 3 syntheses or guidelines pooled it, 451 citations in OpenAlex.
- Systematic Review: Prognostic Molecular Biomarkers in Wilms Tumors.JCO precision oncology · 2026Pooled it
- Risk factors of neuroblastoma: a systematic review and meta-analysis.Frontiers in public health · 2025Pooled it
- Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.International journal of clinical oncology · 2024Guideline
- Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Otoprotective Effects of Sodium Thiosulfate by Demographic and Clinical Characteristics: A Report From Children's Oncology Group Study ACCL0431.Pediatric blood & cancer · 2025Trial
- DMAMCL induces ferroptosis in neuroblastoma by targeting HMOX1 in MYCN-amplified subtypes whereas targeting STEAP3 in MYCN-nonamplified subtypes.Redox report : communications in free radical research · 2026Article
- Diagnostic performance of multiparametric model integrating ¹⁸F-MFBG PET/CT imaging parameters and clinical factors for differentiating neuroblastoma from ganglioneuroblastoma: a preliminary study.European journal of nuclear medicine and molecular imaging · 2026Article
- Machine learning prediction model for distant metastasis at diagnosis in pediatric neuroblastoma: development, interpretation, and temporal validation.Translational pediatrics · 2026Article
- Engineered Allosteric Biosensor for In Situ DNA Glycosylase Detection in Neuroblastoma Risk Stratification and Drug Resistance Monitoring.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Integrated miRNA-Target Gene Analysis Reveals Complementary Molecular Biomarkers and Regulatory Networks in Pediatric Neuroblastoma.International journal of molecular sciences · 2026Article
- Electromagnetic Surgical Navigation for Accurate Pediatric Tumor Localization: A Preclinical Animal Cadaver Study.Cancers · 2026Article
- Integrated Genomic and Proteomic Analysis Reveals T-B Lymphocyte Signatures in the MYCN Driven "Immune Desert" of Specific Neuroblastoma Subtypes.CNS neuroscience & therapeutics · 2026Article
- Pediatric endocrine disorders: a review of intra-abdominal findings and appropriate imaging.Pediatric radiology · 2026Review
- Triple-amplified sequential activation allosteric DNA biosensor forRSC advances · 2026Article
- A functional landscape for chromosome 17q in neuroblastoma: balancing replication stress and genomic stability.British journal of cancer · 2026Review
- Neuroblastoma Metastasis to the Mandible in Children: A Case Report and Focused Narrative Review of Reported Cases.Children (Basel, Switzerland) · 2026Article
- Molecular Imaging Tools for Improved Risk Stratification of Pediatric Neuroblastoma.Radiology. Imaging cancer · 2026Article
- Article
- Bevacizumab added to conventional induction chemotherapy for children with high risk neuroblastoma (BRAVEN trial).Discover oncology · 2026Article
- Targeting the MYCN interaction network in neuroblastoma.Bioscience reports · 2026Review
249 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 11 institutions in 2 countries.
Funding
Abstract
purposeTreatment planning for children with neuroblastoma requires accurate assessment of prognosis. The most recent Children's Oncology Group (COG) risk classification system used tumor stage as defined by the International Neuroblastoma Staging System. Here, we validate a revised classifier using the International Neuroblastoma Risk Group Staging System (INRGSS) and incorporate segmental chromosome aberrations (SCA) as an additional genomic biomarker.
methodsNewly diagnosed patients enrolled on the COG neuroblastoma biology study ANBL00B1 between 2007 and 2017 with known age, International Neuroblastoma Staging System, and INRGSS stage were identified (N = 4,832). Tumor
resultsMost patients with locoregional tumors had excellent outcomes except for those with image-defined risk factors (INRGSS L2) with
conclusionA revised 2021 COG neuroblastoma risk classifier (version 2) that uses the INRGSS and incorporates SCAs has been adopted to prospectively define COG clinical trial eligibility and treatment assignment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.